HARRY A OKEN, MD
Osteopathic Medicine at Charter Dr, Columbia, MD
License number
Maryland D0031172
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
10700 Charter Dr SUITE 200, Columbia, MD 21044
Phone
(410) 910-7500
(410) 910-2310 (Fax)
(410) 910-2310 (Fax)
Organization information
See more information about HARRY A OKEN at bizstanding.comHarry A Oken MD
10700 Charter Dr #200, Columbia, MD 21044
Industry:
Internist
Doing business as:
Harry Oken MD
Phone:
(410) 910-2350 (Phone), (410) 910-7444 (Phone)
Harry Andrew Oken
Categories:
Cardiology Physicians & Surgeons, Internal Medicine Physicians & Surgeons
Professional information
Dr. Harry A Oken, Columbia MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine
Address:
10700 Charter Dr STE 200, Columbia 21044
(410) 910-7500 (Phone)
(410) 910-7500 (Phone)
Certifications:
Internal Medicine, 1986
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of Maryland School Of Medicine
Graduated: 1983
University MD
Graduated: 1984
Graduated: 1986
University Of Maryland School Of Medicine
Graduated: 1983
University MD
Graduated: 1984
Graduated: 1986
Harry A Oken, Columbia MD
Specialties:
Internist
Address:
10700 Charter Dr, Columbia, MD 21044
Education:
University of Maryland, School of Medicine - Doctor of Medicine
University of Maryland Medical Center - Fellowship - Internal Medicine
University of Maryland Medical Center - Residency - Internal Medicine
University of Maryland Medical Center - Fellowship - Internal Medicine
University of Maryland Medical Center - Residency - Internal Medicine
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine
Harry Andrew Oken, Columbia MD
Specialties:
Internal Medicine, Diagnostic Ultrasound
Work:
Charter Internal Medicine Llc
10700 Charter Dr, Columbia, MD 21044
10700 Charter Dr, Columbia, MD 21044
Education:
University of Maryland(1983)
Glycemic Control For Prediabetes And/Or Diabetes Type Ii Using Docosahexaenoic Acid
US Patent:
2004009, May 13, 2004
Filed:
Sep 29, 2003
Appl. No.:
10/672077
Inventors:
Linda Arterburn - Ellicott City MD, US
Diane Benisek - Severna Park MD, US
James Hoffman - Blue Bell PA, US
Harry Oken - Columbia MD, US
Mary Van Elswyk - St. Longmont CO, US
Diane Benisek - Severna Park MD, US
James Hoffman - Blue Bell PA, US
Harry Oken - Columbia MD, US
Mary Van Elswyk - St. Longmont CO, US
International Classification:
A61K038/28, A61K031/426, A61K031/202, A61K031/175
US Classification:
514/560000, 514/003000, 514/365000, 514/592000
Abstract:
This invention is directed to methods of treating patients with metabolic syndrome, prediabetes and/or Type II diabetes mellitus by administering docosahexaenoic acid (DHA) alone or in combination with diabetes-related medications.
Prophylactic Docosahexaenoic Acid Therapy For Patients With Subclinical Inflammation
US Patent:
2009020, Aug 13, 2009
Filed:
Feb 3, 2009
Appl. No.:
12/364893
Inventors:
Linda Arterburn - Ellicott City MD, US
James Hoffman - Blue Bell PA, US
Harry Oken - Columbia MD, US
Mary Van Elswyk - Longmont CO, US
James Hoffman - Blue Bell PA, US
Harry Oken - Columbia MD, US
Mary Van Elswyk - Longmont CO, US
Assignee:
Martek Biosciences Corporation - Columbia MD
International Classification:
A61K 31/202, A61P 29/00, A61K 31/60, A61K 31/4365, A61P 3/00
US Classification:
514163, 514560, 514301
Abstract:
This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.
Prophylactic Docosahexaenoic Acid Therapy For Patients With Subclinical Inflammation
US Patent:
2006006, Mar 30, 2006
Filed:
Sep 12, 2005
Appl. No.:
11/223128
Inventors:
Linda Arterburn - Ellicott City MD, US
James Hoffman - Blue Bell PA, US
Harry Oken - Columbia MD, US
Mary Van Elswyk - Longmont CO, US
James Hoffman - Blue Bell PA, US
Harry Oken - Columbia MD, US
Mary Van Elswyk - Longmont CO, US
Assignee:
Martek Biosciences Corporation - Columbia MD
International Classification:
A61K 31/202
US Classification:
514560000
Abstract:
This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.
Prophylactic Docosahexaenoic Acid Therapy For Patients With Subclinical Inflammation
US Patent:
2004010, Jun 3, 2004
Filed:
Sep 29, 2003
Appl. No.:
10/672059
Inventors:
Linda Arterburn - Ellicott City MD, US
James Hoffman - Blue Bell PA, US
Harry Oken - Columbia MD, US
Mary Van Elswyk - Longmont CO, US
James Hoffman - Blue Bell PA, US
Harry Oken - Columbia MD, US
Mary Van Elswyk - Longmont CO, US
International Classification:
A61K031/60, A61K031/4743, A61K031/202
US Classification:
514/165000, 514/560000, 514/301000
Abstract:
This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly associated with atherosclerotic cardiovascular disease, coronary disease or cerebrovascular disease. The methods and compositions of the invention are also particularly suited to providing therapy for subclinical inflammation in diabetic and prediabetic patients. Methods of the invention comprise administration of DHA alone and in combination with antiplatelet drugs.